Sunday, 26th June 2022
<To guardian.ng
Search

Oxford Covid-19 vaccine trial shows similar effects in older and younger adults

The Oxford coronavirus vaccine shows a strong immune response in adults in their 60s and 70s, raising hopes that it can protect age groups most at risk from the virus.

Related

10 Apr 2020
Dino Melaye to Africans - We must unite against Covid-19 vaccine trial
25 Apr 2020
With more than 2.5 million people now infected worldwide in the COVID-19 pandemic, Germany has authorized the first clinical trial of a coronavirus vaccine. The first human tests will begin before the end of April.
23 Apr 2020
Here is why you should pick a copy of The Guardian on Friday. Find these stories and much more when you grab a copy of The Guardian on the newsstands on Friday.⁣
21 Jul 2020
The French paper Libération speaks to an exiled Uighur who details the brutal persecution campaign led by Chinese authorities, including confirmation of forced sterilisations. Also, the British press is extremely hopeful over a promising Oxford research team's vaccine trial. Plus, find out why Zoom meetings have led to a rise in casual workwear and... a spike in demand for cosmetic surgery!
13 Sep 2020
Pharmaceutical company AstraZeneca says it has "voluntarily paused" a randomized clinical trial of its coronavirus vaccine in what it called a routine action after a volunteer developed an unexplained illness.
11 Nov 2020
Pfizer and BioNTech have chosen RNA messenger technology for their vaccine. It is made up of lab-made RNA strands containing the code for the same protein that allows coronavirus to enter cells.
19 Nov 2020
The Oxford coronavirus vaccine shows a strong immune response in adults in their 60s and 70s, raising hopes that it can protect age groups most at risk from the virus.
2 Jan 2021
DW correspondent Sergey Satanovskiy is participating in the Russian Sputnik V COVID-19 vaccine trial. He does not know whether he is receiving the actual vaccine or a placebo. This is the second part of his report.
2 Oct 2021
The BioNTech/Pfizer vaccine for 5 to 11 year olds could be approved in the US as early as October. Meanwhile, Australia plans to stop paying workers affected by lockdowns. Follow DW for the latest.